Szerző: " Vajas Attila"

David M Brown; David S Boyer; Diana V Do; Charles C Wykoff; Taiji Sakamoto; Peter Win; Sunir Joshi; Hani Salehi-Had; Seres András; Alyson J Berliner; Sergio Leal; Robert Vitti; Karen W Chu; Kimberly Reed; Rohini Rao; Yenchieh Cheng; Wei Sun; Delia Voronca; Rafia Bhore; Ursula Schmidt-Ott; Thomas Schmelter; Andrea Schulze; Xin Zhang; Boaz Hirshberg; George D Yancopoulos; Sobha Sivaprasad; Kollaborációs szervezet: PHOTON Investigators; Bátor György; Kerényi Ágnes; Kiss Katalin; Milibák Tibor; Papp András; Seres András; Tóth-Molnár Edit; Vajas Attila; Varsányi Balázs: Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON) : 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
LANCET, 403 (10432). pp. 1153-1163. ISSN 0140-6736 (2024)

Woo Se Joon; Sadda SriniVas R; Bradvica Mario; Vajas Attila; Sagong Min; Ernest Jan; Studnička Jan; Veith Miroslav; Wylegala Edward; Patel Sunil; Yun Cheolmin; Orski Michal; Astakhov Sergei; Tóth-Molnár Edit; Csutak Adrienne; Enyedi Lajos; Choi Wooree; Oh Inkyung; Jang Hyerin: Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial.
BMJ OPEN OPHTHALMOLOGY, 8 (1). ISSN 2397-3269 (2023)

Woo Se Joon; Bradvica Mario; Vajas Attila; Sagong Min; Ernest Jan; Studnicka Jan; Veith Miroslav; Wylegala Edward; Patel Sunil; Yun Cheolmin; Orski Michal; Astakhov Sergei; Tóth-Molnár Edit; Csutak Adrienne; et al.: Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration A Phase 3 Randomized Clinical Trial.
JAMA OPHTHALMOLOGY, 141 (7). pp. 668-676. ISSN 2168-6165 (2023)

Shimura Masahiko; Kitano Shigehiko; Ogata Nahoko; Mitamura Yoshinori; Oh Hideyasu; Kollaborációs szervezet: YOSEMITE and RHINE Investigators; Bátor György; Seres András; Szalczer Lajos; Tóth-Molnár Edit; Vajas Attila; Varsány Balázs; Kerény Ágnes; Papp András; Szecskó Tímea; Vogt Gábor: Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1‑year results from the Japan subgroup of the phase 3 YOSEMITE trial.
JAPANESE JOURNAL OF OPHTHALMOLOGY, 67 (3). pp. 264-279. ISSN 0021-5155 (2023)